TrumpRx, the Trump administration’s much-anticipated direct-to-consumer drug platform, went live on Thursday. However, it ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

A new drug for obesity is delivering promising results and could challenge Wegovy.

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

Pfizer Inc. revealed data from one of its new obesity treatments early Tuesday with little detail, leaving investors wondering if the up to $10 billion it spent purchasing the company that created the ...

Swiss pharmaceutical giant Roche announced positive results from a Phase II trial of its obesity drug CT-388, which showed ...

The MarketWatch News Department was not involved in the creation of this content. ARLINGTON, Va., Jan. 13, 2026 /PRNewswire/ -- Today, the Obesity Association(TM), a division of the American Diabetes ...

With the supply of GLP-1 medications finally stabilizing as their use skyrocketed 600% among Americans from 2018 to 2024, the pharmaceutical landscape for anti-obesity medications is now poised to ...

ARLINGTON, Va., Jan. 13, 2026 /PRNewswire/ -- Today, the Obesity Association™, a division of the American Diabetes Association® (Obesity Association), announced the publication of the next section in ...